MXPA02011543A - Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada. - Google Patents
Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada.Info
- Publication number
- MXPA02011543A MXPA02011543A MXPA02011543A MXPA02011543A MXPA02011543A MX PA02011543 A MXPA02011543 A MX PA02011543A MX PA02011543 A MXPA02011543 A MX PA02011543A MX PA02011543 A MXPA02011543 A MX PA02011543A MX PA02011543 A MXPA02011543 A MX PA02011543A
- Authority
- MX
- Mexico
- Prior art keywords
- suspension
- viscosity
- injectability
- preparation
- improved injectability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Abstract
Composiciones inyectables las cuales tienen capacidad de inyeccion mejorada. Las composiciones inyectables incluyen microparticuias en un vehiculo acuoso de inyeccion el cual tiene una viscosidad de por lo menos 20 cp en 20 degree C. La viscosidad incrementada del vehiculo de inyeccion que constituye la fase fluida de la suspension reduce significativamente las fallas de capacidad de inyeccion in vivo. Las composiciones inyectables pueden ser hechas por mezclar microparticulas secas con un vehiculo acuoso de inyeccion para formar una suspension, y despues mezclar la suspension con un agente de incremento de viscosidad para incrementar la viscosidad de la fase fluida de la suspension al nivel deseado para capacidad de inyeccion mejorada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/577,875 US6495164B1 (en) | 2000-05-25 | 2000-05-25 | Preparation of injectable suspensions having improved injectability |
PCT/US2001/012652 WO2001091720A2 (en) | 2000-05-25 | 2001-04-19 | Preparation of injectable suspensions having improved injectability |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02011543A true MXPA02011543A (es) | 2004-08-12 |
Family
ID=24310496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02011543A MXPA02011543A (es) | 2000-05-25 | 2001-04-19 | Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada. |
Country Status (27)
Country | Link |
---|---|
US (7) | US6495164B1 (es) |
EP (4) | EP3095442B1 (es) |
JP (1) | JP4502355B2 (es) |
KR (1) | KR100810480B1 (es) |
CN (1) | CN100453067C (es) |
AT (1) | ATE363891T1 (es) |
AU (2) | AU2001255463B2 (es) |
BG (1) | BG66023B1 (es) |
BR (1) | BRPI0111060B8 (es) |
CA (1) | CA2406536C (es) |
CY (3) | CY1107441T1 (es) |
CZ (1) | CZ301359B6 (es) |
DE (1) | DE60128798T2 (es) |
DK (3) | DK1754469T3 (es) |
ES (3) | ES2572877T3 (es) |
HK (4) | HK1103346A1 (es) |
HU (1) | HU228587B1 (es) |
IL (1) | IL152767A (es) |
IS (1) | IS2471B (es) |
MX (1) | MXPA02011543A (es) |
NO (1) | NO334660B1 (es) |
NZ (1) | NZ522335A (es) |
PL (1) | PL204298B1 (es) |
PT (2) | PT1283699E (es) |
RU (1) | RU2002135641A (es) |
SI (2) | SI1754469T1 (es) |
WO (1) | WO2001091720A2 (es) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US6770478B2 (en) * | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
KR100525189B1 (ko) * | 2002-10-10 | 2005-10-31 | 메디칸(주) | 고체를 이용한 생체 부피 대체를 위한 주사용 소재 |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
EP1589901A4 (en) * | 2002-12-20 | 2006-08-09 | Generipharm Inc | INTRACUTANEOUS INJECTION |
WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
SI1603513T1 (sl) * | 2003-03-04 | 2021-04-30 | Lyotropic Therapeutics, Inc. | Sestavki dantrolena |
WO2004103342A2 (en) * | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
PL1660009T3 (pl) * | 2003-09-03 | 2015-08-31 | Miscon Trading S A | Sposoby leczenia endometriozy |
US8092527B2 (en) * | 2003-09-03 | 2012-01-10 | Brennan William A | System and method for breast augmentation |
US7169180B2 (en) * | 2003-09-03 | 2007-01-30 | Brennan William A | System and method for breast augmentation |
US7906125B2 (en) * | 2003-09-18 | 2011-03-15 | Boston Scientific Scimed, Inc. | Solid or semi-solid therapeutic formulations |
US20050064045A1 (en) * | 2003-09-18 | 2005-03-24 | Sheng-Ping Zhong | Injectable therapeutic formulations |
EP1675573B2 (en) * | 2003-10-23 | 2012-06-13 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
KR101144647B1 (ko) * | 2003-10-31 | 2012-05-08 | 와카모토 세이야꾸 가부시끼가이샤 | 가역성 열 겔화 수성 조성물 |
EA200601904A1 (ru) | 2004-04-15 | 2007-02-27 | Алкермес, Инк. | Система отсроченного высвобождения лекарственного средства на основе полимеров |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20060110423A1 (en) * | 2004-04-15 | 2006-05-25 | Wright Steven G | Polymer-based sustained release device |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
US8236292B2 (en) * | 2004-06-04 | 2012-08-07 | Camurus Ab | Liquid depot formulations |
ITMI20041245A1 (it) * | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US8318210B2 (en) * | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US20060251581A1 (en) * | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
SI1971362T1 (sl) | 2005-08-19 | 2015-03-31 | Amylin Pharmaceuticals, Llc | Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
WO2007061896A1 (en) | 2005-11-17 | 2007-05-31 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
US20090038701A1 (en) * | 2006-01-17 | 2009-02-12 | Baxter International Inc. | Device, system and method for mixing |
CA2651855C (en) | 2006-05-30 | 2011-08-02 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
JP4941977B2 (ja) * | 2007-04-11 | 2012-05-30 | 大蔵製薬株式会社 | ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物 |
ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
NZ597621A (en) | 2007-05-25 | 2013-06-28 | Tolmar Therapeutics Inc | Sustained delivery formulations of risperidone compounds |
US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
SI2170287T1 (sl) | 2007-07-26 | 2014-04-30 | Aqtis Ip Bv | Mikrodelci, ki vsebujejo pcl in njihova uporaba |
PT2170279T (pt) * | 2007-07-31 | 2018-04-06 | Otsuka Pharma Co Ltd | Métodos para produção de suspensão de aripiprazole e formulação liofilizada |
WO2009056990A2 (en) * | 2007-08-21 | 2009-05-07 | Actavis Group Ptc Ehf | Paliperidone polymorphs |
US9987221B2 (en) * | 2007-08-23 | 2018-06-05 | Boston Scientific Scimed, Inc. | Injectable hydrogel compositions |
KR20100067684A (ko) * | 2007-11-05 | 2010-06-21 | 보오슈 앤드 롬 인코포레이팃드 | 약물 전달을 위한 비히클로서의 수불혼화성 물질 |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2009134336A1 (en) | 2008-04-28 | 2009-11-05 | Zogenix, Inc. | Novel formulations for treatment of migraine |
ES2552646T3 (es) | 2008-05-21 | 2015-12-01 | Amylin Pharmaceuticals, Inc. | Exendinas para disminuir el colesterol y los triglicéridos |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
DK2774608T3 (da) | 2008-06-16 | 2020-01-13 | Pfizer | Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf |
WO2009158724A2 (en) * | 2008-06-27 | 2009-12-30 | Tepha, Inc. | Improved injectable delivery of microparticles and compositions therefore |
KR101760953B1 (ko) | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
US20100063879A1 (en) * | 2008-09-05 | 2010-03-11 | Yellowpages.Com Llc | Systems and Methods to Selectively Provide Information Based on User Interest |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN102811743B (zh) | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
EA201290499A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами |
EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
CN107595771A (zh) | 2010-10-18 | 2018-01-19 | 大日本住友制药株式会社 | 注射用缓释制剂 |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2683364B1 (en) | 2011-03-10 | 2017-01-18 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
CN103930096B (zh) | 2011-10-31 | 2017-05-31 | Xeris药物公司 | 用于治疗糖尿病的制剂 |
AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
AU2013232297B2 (en) | 2012-03-16 | 2016-01-14 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
CA2867203C (en) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
RS61377B1 (sr) | 2012-07-26 | 2021-02-26 | Camurus Ab | Opioidne formulacije |
HUE043998T2 (hu) | 2012-09-17 | 2019-09-30 | Pfizer | Eljárás terápiás nanorészecskék elõállítására |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
EP3104840B8 (en) * | 2014-02-11 | 2019-07-10 | Latitude Pharmaceuticals Inc. | Parenteral compositions of celecoxib |
WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
CA2942859A1 (en) | 2014-03-14 | 2015-09-17 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
KR20170044199A (ko) * | 2014-08-28 | 2017-04-24 | 더 제너럴 하스피탈 코포레이션 | 신경 질환을 치료하기 위한 조성물 및 방법 |
US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MX2017007873A (es) | 2014-12-15 | 2017-11-06 | Univ Johns Hopkins | Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares. |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
US20160303281A1 (en) | 2015-04-17 | 2016-10-20 | Rochal Industries, Llc | Composition and kits for pseudoplastic microgel matrices |
US10660937B2 (en) | 2015-05-22 | 2020-05-26 | The Board Of Trustees Of The Leland Stanford Junio | Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39) |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
CN107690333B (zh) | 2015-06-10 | 2021-12-17 | 赢创运营有限公司 | 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法 |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
NZ740665A (en) | 2015-09-21 | 2023-04-28 | Teva Pharmaceuticals Int Gmbh | Sustained release olanzapine formulations |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
CN105310980A (zh) * | 2015-10-09 | 2016-02-10 | 北京万全德众医药生物技术有限公司 | 帕利哌酮缓释混悬口服液及其制备方法 |
WO2017083779A1 (en) | 2015-11-12 | 2017-05-18 | Graybug Vision, Inc. | Aggregating microparticles for therapy |
FI3377041T3 (fi) | 2015-11-16 | 2023-11-30 | Medincell S A | Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen |
SG10201913504XA (en) | 2016-02-26 | 2020-03-30 | Massachusetts Gen Hospital | Medical ice slurry production and delivery systems and methods |
US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
KR20240037175A (ko) | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CA3029262A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
EP3478294A4 (en) | 2016-07-01 | 2020-06-10 | G1 Therapeutics, Inc. | PYRIMIDINE-BASED ANTIPROLIFERATIVE ACTIVE SUBSTANCES |
US20190224122A1 (en) | 2016-09-23 | 2019-07-25 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
WO2018094404A1 (en) | 2016-11-21 | 2018-05-24 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10350200B2 (en) * | 2017-01-23 | 2019-07-16 | Southwest Research Institute | Aqueous suspensions of oximes for autoinjectors |
WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
MX2019011242A (es) | 2017-03-23 | 2020-01-21 | Graybug Vision Inc | Farmacos y composiciones para el tratamiento de trastornos oculares. |
CN111201040A (zh) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
KR20240036128A (ko) | 2017-06-02 | 2024-03-19 | 엑스에리스 파머수티클스, 인크. | 침전 방지 저분자 약물 제제 |
US10568842B2 (en) * | 2017-08-18 | 2020-02-25 | Lance L. Gooberman | Anti-inflammatory pharmaceutical compositions and methods of administration |
CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
EP3841086A4 (en) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D |
KR102639578B1 (ko) * | 2018-10-15 | 2024-02-21 | 주식회사 종근당 | 주사 가능한 장기-지속형 날트렉손 마이크로입자 조성물 |
CN113365617A (zh) | 2018-10-16 | 2021-09-07 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
EP4084828A4 (en) * | 2020-01-03 | 2024-03-13 | Privo Tech Inc | PHARMACEUTICAL SYSTEMS AND COMPOSITIONS FOR THE TREATMENT OF A TARGETED POPULATION OF CELLS BY DIRECT INJECTION |
BE1028769B1 (nl) * | 2020-11-02 | 2022-05-31 | Flanders Color Nv | Watergedragen vloeibare spoellak |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
US11241330B1 (en) | 2021-04-02 | 2022-02-08 | Brixton Biosciences, Inc. | Apparatus for creation of injectable slurry |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
CN114146020B (zh) * | 2022-02-10 | 2022-04-29 | 中国远大集团有限责任公司 | 一种注射美容产品及其制备方法和应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL137652C (es) | 1962-07-11 | |||
BE744162A (fr) | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | Procede d'encapsulage |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
US3700215A (en) * | 1970-10-21 | 1972-10-24 | Hardman Inc | Mixing and dispensing device |
JPS523342B2 (es) | 1972-01-26 | 1977-01-27 | ||
GB1413186A (en) | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
US4029782A (en) * | 1975-04-28 | 1977-06-14 | Eli Lilly And Company | Cefazolin suspension for parenteral administration |
JPS523653A (en) | 1975-06-27 | 1977-01-12 | Fuji Photo Film Co Ltd | Process for producing fine polymer particles |
IL51791A0 (en) * | 1976-04-14 | 1977-05-31 | Exxon Research Engineering Co | New injectable medicinal compositions |
US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
JPS60112713A (ja) * | 1983-11-21 | 1985-06-19 | Sumitomo Chem Co Ltd | 有用な徐放性注射剤 |
US5385738A (en) | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
JPH0657658B2 (ja) * | 1985-04-11 | 1994-08-03 | 住友製薬株式会社 | 徐放性製剤 |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
AU2810189A (en) | 1987-10-30 | 1989-05-23 | Stolle Research & Development Corporation | Low residual solvent microspheres and microencapsulation process |
US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
IL92344A0 (en) | 1989-01-04 | 1990-07-26 | Gist Brocades Nv | Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1990013361A1 (en) | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
US5478564A (en) | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
HU222501B1 (hu) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
US20020009443A1 (en) * | 1991-12-02 | 2002-01-24 | Vanitha Ramakrishman | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
US5658593A (en) | 1992-01-16 | 1997-08-19 | Coletica | Injectable compositions containing collagen microcapsules |
US6537574B1 (en) * | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
JP3267972B2 (ja) | 1992-02-28 | 2002-03-25 | コラーゲン コーポレイション | 高濃度均質化コラーゲン組成物 |
US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
WO1993019739A1 (en) | 1992-03-30 | 1993-10-14 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
CA2148823C (en) | 1992-11-17 | 1999-03-09 | Welfide Corporation | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
EP0674506B1 (en) | 1992-12-02 | 2000-08-23 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
MY113268A (en) * | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
TW376319B (en) | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
JPH09505308A (ja) | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | 生物学的活性剤を含有する生分解性微粒子の製造 |
SI0729357T1 (en) | 1993-11-19 | 2005-06-30 | Janssen Pharmaceutica N.V. | Microencapsulated 1,2-benzazoles |
US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
AU706541B2 (en) * | 1995-06-09 | 1999-06-17 | Euro-Celtique S.A. | Formulations and methods for providing prolonged local anesthesia |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
SE505146C2 (sv) | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
ATE508733T1 (de) * | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
KR100367144B1 (ko) | 1997-07-02 | 2003-01-14 | 유로-셀티크 소시에떼 아노뉨 | 관절과 체강(body space)내에서 연장된 마취 |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
JP2000039867A (ja) * | 1998-05-18 | 2000-02-08 | Fujitsu Ltd | プラズマディスプレイ装置およびプラズマディスプレイパネルの駆動方法 |
US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
US6306425B1 (en) * | 1999-04-09 | 2001-10-23 | Southern Research Institute | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
AU765496C (en) | 1999-08-27 | 2005-08-25 | Brookwood Pharmaceuticals Inc. | Injectable buprenorphine microparticle compositions and their use |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
-
2000
- 2000-05-25 US US09/577,875 patent/US6495164B1/en not_active Expired - Lifetime
-
2001
- 2001-04-19 MX MXPA02011543A patent/MXPA02011543A/es active IP Right Grant
- 2001-04-19 ES ES06010734.9T patent/ES2572877T3/es not_active Expired - Lifetime
- 2001-04-19 DK DK06010734.9T patent/DK1754469T3/en active
- 2001-04-19 PT PT01928628T patent/PT1283699E/pt unknown
- 2001-04-19 SI SI200131050A patent/SI1754469T1/sl unknown
- 2001-04-19 DK DK01928628T patent/DK1283699T3/da active
- 2001-04-19 BR BR0111060A patent/BRPI0111060B8/pt not_active IP Right Cessation
- 2001-04-19 RU RU2002135641/15A patent/RU2002135641A/ru not_active Application Discontinuation
- 2001-04-19 IL IL152767A patent/IL152767A/en active IP Right Grant
- 2001-04-19 AU AU2001255463A patent/AU2001255463B2/en not_active Expired
- 2001-04-19 HU HU0302283A patent/HU228587B1/hu unknown
- 2001-04-19 EP EP16161468.0A patent/EP3095442B1/en not_active Expired - Lifetime
- 2001-04-19 AU AU5546301A patent/AU5546301A/xx active Pending
- 2001-04-19 DE DE60128798T patent/DE60128798T2/de not_active Expired - Lifetime
- 2001-04-19 EP EP06010734.9A patent/EP1754469B1/en not_active Revoked
- 2001-04-19 JP JP2001587736A patent/JP4502355B2/ja not_active Expired - Lifetime
- 2001-04-19 SI SI200131051A patent/SI2269577T1/sl unknown
- 2001-04-19 PL PL365195A patent/PL204298B1/pl unknown
- 2001-04-19 NZ NZ522335A patent/NZ522335A/en not_active IP Right Cessation
- 2001-04-19 ES ES01928628T patent/ES2286118T3/es not_active Expired - Lifetime
- 2001-04-19 ES ES10174743.4T patent/ES2574823T3/es not_active Expired - Lifetime
- 2001-04-19 EP EP01928628A patent/EP1283699B1/en not_active Expired - Lifetime
- 2001-04-19 CZ CZ20023848A patent/CZ301359B6/cs not_active IP Right Cessation
- 2001-04-19 KR KR1020027015892A patent/KR100810480B1/ko active IP Right Grant
- 2001-04-19 CN CNB01809967XA patent/CN100453067C/zh not_active Expired - Lifetime
- 2001-04-19 DK DK10174743.4T patent/DK2269577T3/en active
- 2001-04-19 EP EP10174743.4A patent/EP2269577B1/en not_active Revoked
- 2001-04-19 WO PCT/US2001/012652 patent/WO2001091720A2/en active IP Right Grant
- 2001-04-19 PT PT101747434T patent/PT2269577E/pt unknown
- 2001-04-19 AT AT01928628T patent/ATE363891T1/de active
- 2001-04-19 CA CA002406536A patent/CA2406536C/en not_active Expired - Lifetime
-
2002
- 2002-09-30 US US10/259,949 patent/US6667061B2/en not_active Expired - Lifetime
- 2002-10-28 IS IS6595A patent/IS2471B/is unknown
- 2002-10-28 NO NO20025164A patent/NO334660B1/no not_active IP Right Cessation
- 2002-11-19 BG BG107288A patent/BG66023B1/bg unknown
-
2003
- 2003-07-18 HK HK07107885.6A patent/HK1103346A1/zh not_active IP Right Cessation
- 2003-07-18 HK HK03105214A patent/HK1054319A1/xx not_active IP Right Cessation
- 2003-10-09 US US10/681,142 patent/US7371406B2/en not_active Expired - Lifetime
- 2003-11-27 HK HK03108656.5A patent/HK1056321A1/xx not_active IP Right Cessation
-
2007
- 2007-07-19 US US11/826,995 patent/US20080044478A1/en not_active Abandoned
- 2007-07-19 US US11/826,994 patent/US7799345B2/en not_active Expired - Lifetime
- 2007-08-09 CY CY20071101070T patent/CY1107441T1/el unknown
-
2010
- 2010-08-13 US US12/856,198 patent/US20100303900A1/en not_active Abandoned
-
2011
- 2011-07-05 HK HK11106882.5A patent/HK1152660A1/zh not_active IP Right Cessation
-
2013
- 2013-11-20 US US14/085,051 patent/US20140193507A1/en not_active Abandoned
-
2016
- 2016-06-10 CY CY20161100509T patent/CY1117734T1/el unknown
- 2016-06-16 CY CY20161100537T patent/CY1117652T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02011543A (es) | Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada. | |
WO2001028591A3 (en) | Injection vehicle for polymer-based formulations | |
BR0212164A (pt) | Limpador espessado para vaso sanitário | |
WO2002000171A3 (en) | Composition for delivery of hematopoietic growth factor | |
PE84899A1 (es) | Formulaciones farmaceuticas que contienen voriconazol | |
AR048681A1 (es) | Composiciones blanqueadoras liquidas | |
AR023304A1 (es) | Composiciones champu | |
WO2002101412A3 (en) | Spray freeze-dried compositions | |
MY126973A (en) | Derivatives of 4-aminopiperidine and their use as a medicament | |
CA2390824A1 (en) | Stabilized aqueous acidic antiperspirant compositions and related methods | |
WO2002038185A3 (en) | Injectable sustained release delivery system with loperamide | |
AR041826A1 (es) | Formulaciones de liberacion prolongada en formas de suspension | |
BR0214602A (pt) | Método de produção de um tablete detergente, tablete detergente, e, componente de argila adequado para uso em uma formulação detergente | |
DE60223542D1 (de) | Zusammensetzung mit fulvestrant | |
AR036828A1 (es) | Composicion de sellado y su uso. | |
EP1266875A3 (en) | Slurry rheology modifier | |
DE50009804D1 (de) | Vernetzerfreie zubereitungen | |
CN204670812U (zh) | 一种水暖毯 | |
GR1003679B (el) | Συνθεση διαλυματος καλλιεργειας κονιοποιημενου aureobacidium, μεθοδος παρασκευης της και μιγμα της συνθεσης υπο μορφη σκονης. | |
BR0013266A (pt) | Composição, utilização de uma composição e artigo acabado | |
RU98100126A (ru) | Способ гидравлического разрыва пласта | |
Jiang et al. | Study on the miscibility of dynamically vulcanized EPDM/PP blend by positron annihilation spectroscopy | |
CN107753991A (zh) | 一种汽车后备箱除臭剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |